WO1998055607A3 - Tumor targeted vector - Google Patents
Tumor targeted vector Download PDFInfo
- Publication number
- WO1998055607A3 WO1998055607A3 PCT/GB1998/001627 GB9801627W WO9855607A3 WO 1998055607 A3 WO1998055607 A3 WO 1998055607A3 GB 9801627 W GB9801627 W GB 9801627W WO 9855607 A3 WO9855607 A3 WO 9855607A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- tumor targeted
- targeted vector
- vector
- noi
- poi
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/485—Epidermal growth factor [EGF] (urogastrone)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70532—B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus
Abstract
Priority Applications (17)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NZ500633A NZ500633A (en) | 1997-06-04 | 1998-06-04 | Vector |
AU77801/98A AU747602B2 (en) | 1997-06-04 | 1998-06-04 | Vector |
US09/445,375 US6852703B1 (en) | 1997-06-04 | 1998-06-04 | Tumor targeted vector |
KR19997011207A KR20010013219A (en) | 1997-06-04 | 1998-06-04 | Vector |
AT98925827T ATE444358T1 (en) | 1997-06-04 | 1998-06-04 | TUMOR TARGETED VECTOR |
DE69841204T DE69841204D1 (en) | 1997-06-04 | 1998-06-04 | Tumor targeted vector |
DK98925827.2T DK1012259T3 (en) | 1997-06-04 | 1998-06-04 | Tumor-directed vector |
EP98925827A EP1012259B1 (en) | 1997-06-04 | 1998-06-04 | Tumor targeted vector |
CA002292760A CA2292760A1 (en) | 1997-06-04 | 1998-06-04 | Vector |
JP50185899A JP2002507117A (en) | 1997-06-04 | 1998-06-04 | vector |
IL13259698A IL132596A0 (en) | 1997-06-04 | 1998-06-04 | Vector |
NO995901A NO995901L (en) | 1997-06-04 | 1999-12-02 | Vector |
US10/104,522 US7531648B2 (en) | 1997-06-04 | 2002-03-22 | Vector encoding an antibody that binds 5T4 antigen |
US11/380,188 US7718627B2 (en) | 1997-06-04 | 2006-04-25 | Vector |
US11/834,649 US20080175819A1 (en) | 1997-06-04 | 2007-08-06 | Vector system |
US12/186,839 US20090017532A1 (en) | 1997-06-04 | 2008-08-06 | Vector |
US12/714,264 US8084249B2 (en) | 1997-06-04 | 2010-02-26 | Vector |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9711579.4A GB9711579D0 (en) | 1997-06-04 | 1997-06-04 | Therapeutic genes |
GB9711579.4 | 1997-06-04 | ||
GB9713150.2 | 1997-06-20 | ||
GBGB9713150.2A GB9713150D0 (en) | 1997-06-20 | 1997-06-20 | Fusion proteins |
GB9714230.1 | 1997-07-04 | ||
GBGB9714230.1A GB9714230D0 (en) | 1997-07-04 | 1997-07-04 | Therapeutic genes |
Related Child Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/445,375 A-371-Of-International US6852703B1 (en) | 1997-06-04 | 1998-06-04 | Tumor targeted vector |
US09445375 A-371-Of-International | 1998-06-04 | ||
PCT/GB2000/004317 Continuation-In-Part WO2001036486A2 (en) | 1997-06-04 | 2000-11-13 | Scfv antibodies against disease associated molecules |
US10/104,522 Division US7531648B2 (en) | 1997-06-04 | 2002-03-22 | Vector encoding an antibody that binds 5T4 antigen |
US10/787,881 Division US20050032216A1 (en) | 1997-06-04 | 2004-02-25 | Vector |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1998055607A2 WO1998055607A2 (en) | 1998-12-10 |
WO1998055607A3 true WO1998055607A3 (en) | 1999-03-04 |
Family
ID=27268875
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB1998/001627 WO1998055607A2 (en) | 1997-06-04 | 1998-06-04 | Tumor targeted vector |
Country Status (16)
Country | Link |
---|---|
US (6) | US6852703B1 (en) |
EP (2) | EP1012259B1 (en) |
JP (3) | JP2002507117A (en) |
CN (1) | CN1224712C (en) |
AT (1) | ATE444358T1 (en) |
AU (1) | AU747602B2 (en) |
CA (1) | CA2292760A1 (en) |
CY (1) | CY1109686T1 (en) |
DE (1) | DE69841204D1 (en) |
DK (1) | DK1012259T3 (en) |
ES (1) | ES2332435T3 (en) |
IL (1) | IL132596A0 (en) |
NO (1) | NO995901L (en) |
NZ (1) | NZ500633A (en) |
PT (1) | PT1012259E (en) |
WO (1) | WO1998055607A2 (en) |
Families Citing this family (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9709421D0 (en) | 1997-05-10 | 1997-07-02 | Zeneca Ltd | Chemical compounds |
US7635687B2 (en) * | 1997-06-04 | 2009-12-22 | Oxford Biomedica (Uk) Limited | Vector system |
AU747602B2 (en) * | 1997-06-04 | 2002-05-16 | Oxford Biomedica (Uk) Limited | Vector |
US7276488B2 (en) * | 1997-06-04 | 2007-10-02 | Oxford Biomedica (Uk) Limited | Vector system |
GB2371803A (en) * | 1999-11-18 | 2002-08-07 | Oxford Biomedica Ltd | Antibodies |
KR20020049054A (en) * | 1999-11-18 | 2002-06-24 | 찰스 굿맨 | Antibodies |
CN1423660A (en) * | 1999-11-18 | 2003-06-11 | 牛津生物医学(英国)有限公司 | Antibodies |
US7575924B2 (en) | 2000-11-13 | 2009-08-18 | Research Development Foundation | Methods and compositions relating to improved lentiviral vectors and their applications |
CA2456169C (en) * | 2001-08-02 | 2012-05-22 | Didier Trono | Methods and compositions relating to improved lentiviral vector production systems |
KR20040054699A (en) * | 2001-10-02 | 2004-06-25 | 엥스띠뛰 끌레이톤 드 라 러쉐르쉬 | Methods and compositions relating to restricted expression lentiviral vectors and their applications |
AU2002337885B1 (en) * | 2001-10-16 | 2003-04-28 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Broadly cross-reactive neutralizing antibodies against human ummunodeficiency virus selected by Env-CD4-co-receptor complexes |
GB0126378D0 (en) * | 2001-11-02 | 2002-01-02 | Oxford Biomedica Ltd | Antigen |
US7939059B2 (en) * | 2001-12-10 | 2011-05-10 | California Institute Of Technology | Method for the generation of antigen-specific lymphocytes |
EP1554392A4 (en) * | 2002-05-06 | 2007-08-08 | Us Gov Health & Human Serv | Identification of novel broadly cross-reactive neutralizing human monoclonal antibodies using sequential antigen panning of phage display libraries |
CA2485120C (en) * | 2002-05-06 | 2013-02-19 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Identification of novel broadly cross-reactive hiv-1 neutralizing human monoclonal antibodies |
KR20050048615A (en) * | 2002-08-19 | 2005-05-24 | 제넨테크, 인크. | Compositions and methods for the diagnosis and treatment of tumor |
GB0300718D0 (en) | 2003-01-13 | 2003-02-12 | Ares Trading Sa | Proteins |
EA009607B1 (en) | 2003-05-21 | 2008-02-28 | Арес Трейдинг С.А. | Tnf-like secreted protein |
EP1621550A1 (en) * | 2004-07-29 | 2006-02-01 | Dompé S.P.A. | Tumor-homing cells engineered to produce tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) |
TW200621282A (en) * | 2004-08-13 | 2006-07-01 | Wyeth Corp | Stabilizing formulations |
AU2005285152A1 (en) * | 2004-09-10 | 2006-03-23 | Wyeth | Humanized anti-5T4 antibodies and anti-5T4 antibody / calicheamicin conjugates |
US20080038280A1 (en) * | 2004-10-14 | 2008-02-14 | Government Of The United States Of America | A32 Monoclonal Antibody Fusion Proteins For Use As Hiv Inhibitors And Vaccines |
EP1807450A2 (en) * | 2004-10-29 | 2007-07-18 | GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Broadly cross-reactive hiv-1 neutralizing human monoclonal antibodies |
GB0426960D0 (en) | 2004-12-08 | 2005-01-12 | Ares Trading Sa | TGR-3 like protein receptor |
CA2645097C (en) | 2006-03-10 | 2019-09-17 | Wyeth | Anti-5t4 antibodies and uses thereof |
US7645860B2 (en) * | 2006-03-31 | 2010-01-12 | Baxter Healthcare S.A. | Factor VIII polymer conjugates |
US7985839B2 (en) * | 2006-03-31 | 2011-07-26 | Baxter International Inc. | Factor VIII polymer conjugates |
US7982010B2 (en) * | 2006-03-31 | 2011-07-19 | Baxter International Inc. | Factor VIII polymer conjugates |
PE20081216A1 (en) | 2006-09-01 | 2008-09-04 | Therapeutic Human Polyclonals Inc | ENHANCED EXPRESSION OF HUMAN OR HUMANIZED IMMUNOGLOBULIN IN NON-HUMAN TRANSGENIC ANIMALS |
JP2010506839A (en) * | 2006-10-12 | 2010-03-04 | ワイス エルエルシー | Methods and compositions with reduced opalescence |
ES2535613T3 (en) * | 2008-07-15 | 2015-05-13 | Oxford Biomedica (Uk) Limited | Immunotherapeutic method |
US20100166808A1 (en) * | 2008-11-17 | 2010-07-01 | Giovanni Marco Pauletti | Method of Facilitating Intracellular Uptake or Transcellular Transport of Cargo Using Nanocarriers Containing Optimal Surface Densities of Integrin-Specific Ligands |
WO2010120266A1 (en) | 2009-04-13 | 2010-10-21 | Inserm, Institut National De La Sante Et De La Recherche Medicale | Hpv particles and uses thereof |
US8809501B2 (en) | 2009-07-27 | 2014-08-19 | Baxter International Inc. | Nucleophilic catalysts for oxime linkage |
NZ623810A (en) | 2009-07-27 | 2015-10-30 | Lipoxen Technologies Ltd | Glycopolysialylation of non-blood coagulation proteins |
US8642737B2 (en) | 2010-07-26 | 2014-02-04 | Baxter International Inc. | Nucleophilic catalysts for oxime linkage |
AU2010277438B2 (en) | 2009-07-27 | 2015-08-20 | Baxalta GmbH | Glycopolysialylation of non-blood coagulation proteins |
CN102497884A (en) * | 2009-07-27 | 2012-06-13 | 巴克斯特国际公司 | Blood coagulation protein conjugates |
NZ612320A (en) | 2010-12-22 | 2015-06-26 | Baxter Healthcare Sa | Materials and methods for conjugating a water soluble fatty acid derivative to a protein |
JP2014533929A (en) | 2011-09-23 | 2014-12-18 | アムゲン リサーチ (ミュンヘン) ゲーエムベーハー | Bispecific binding molecules for 5T4 and CD3 |
US9265969B2 (en) * | 2011-12-21 | 2016-02-23 | Cardiac Pacemakers, Inc. | Methods for modulating cell function |
EP2807485B1 (en) | 2012-01-24 | 2019-03-13 | Pfizer Inc | Methods for detecting 5t4-positive circulating tumor cells and methods of diagnosis of 5t4-positive cancer in a mammalian subject |
US9700639B2 (en) | 2012-02-07 | 2017-07-11 | Aura Biosciences, Inc. | Virion-derived nanospheres for selective delivery of therapeutic and diagnostic agents to cancer cells |
ES2752190T3 (en) | 2012-09-14 | 2020-04-03 | Us Health | Brachyury protein, adenoviral vectors encoding Brachyury protein and their use |
GB201223276D0 (en) * | 2012-12-21 | 2013-02-06 | Ucb Pharma Sa | Antibodies and methods of producing same |
DK3046583T3 (en) | 2013-09-18 | 2019-05-20 | Aura Biosciences Inc | VIRUSLY PARTICLE CONJUGATES FOR TUMOR TREATMENT |
EP3215522B1 (en) | 2014-11-03 | 2021-12-01 | Academisch Ziekenhuis Leiden H.O.D.N. Leids Universitair Medisch Centrum | T cell receptors directed against bob1 and uses thereof |
ES2933030T3 (en) | 2015-03-10 | 2023-01-31 | Academisch Ziekenhuis Leiden H O D N Leids Univ Medisch Centrum | T cell receptors directed against preferentially expressed melanoma antigen and uses thereof |
US10550164B2 (en) | 2015-08-03 | 2020-02-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Brachyury deletion mutants, non-yeast vectors encoding Brachyury deletion mutants, and their use |
EP3184547A1 (en) | 2015-10-29 | 2017-06-28 | F. Hoffmann-La Roche AG | Anti-tpbg antibodies and methods of use |
CN108472365A (en) * | 2015-10-30 | 2018-08-31 | 艾丽塔生物治疗剂公司 | Composition and method for tumour transduction |
US11207339B2 (en) | 2015-10-30 | 2021-12-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Targeted cancer therapy |
WO2017075537A1 (en) | 2015-10-30 | 2017-05-04 | Aleta Biotherapeutics Inc. | Compositions and methods for treatment of cancer |
US11459394B2 (en) | 2017-02-24 | 2022-10-04 | Macrogenics, Inc. | Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof |
US11427645B2 (en) | 2017-03-15 | 2022-08-30 | Oxford Biomedica (Uk) Limited | 5T4-targeting agents and methods |
CN108148905A (en) * | 2018-02-13 | 2018-06-12 | 广州市番禺区中心医院(广州市番禺区人民医院、广州市番禺区心血管疾病研究所) | One section can be as the sequence of depression marker |
CN111886024A (en) | 2018-03-08 | 2020-11-03 | 东莞凡恩世生物医药有限公司 | anti-TIP-1 antibodies and uses thereof |
WO2019175198A2 (en) | 2018-03-12 | 2019-09-19 | Genmab A/S | Antibodies |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1989007947A1 (en) * | 1988-03-04 | 1989-09-08 | Cancer Research Campaign Technology Limited | Improvements relating to antigens |
WO1994011513A1 (en) * | 1992-11-13 | 1994-05-26 | Medical Research Council | Heat shock proteins and the treatment of tumours |
WO1996015238A1 (en) * | 1994-11-16 | 1996-05-23 | Bradley Michael John Stringer | Targeted t lymphocytes |
US5559099A (en) * | 1994-09-08 | 1996-09-24 | Genvec, Inc. | Penton base protein and methods of using same |
WO1996030512A1 (en) * | 1995-03-31 | 1996-10-03 | Rhone-Poulenc Rorer S.A. | Conditional expression system |
WO1996034969A2 (en) * | 1995-05-03 | 1996-11-07 | Canji, Inc. | Gene therapy using replication competent targeted adenoviral vectors |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4997913A (en) * | 1986-06-30 | 1991-03-05 | Oncogen | pH-sensitive immunoconjugates and methods for their use in tumor therapy |
US5591624A (en) * | 1988-03-21 | 1997-01-07 | Chiron Viagene, Inc. | Retroviral packaging cell lines |
JPH04500308A (en) | 1989-05-17 | 1992-01-23 | リサーチ・コーポレーション・テクノロジーズ・インコーポレーテッド | Retrovirus-mediated secretion of recombinant products |
AU6075190A (en) | 1989-06-30 | 1991-01-17 | Regents Of The University Of California, The | Retrovirus detection |
EP0537293A4 (en) | 1990-07-02 | 1993-09-08 | Bristol-Myers Company | Ligand for cd28 receptor on b cells and methods |
GB9109645D0 (en) * | 1991-05-03 | 1991-06-26 | Celltech Ltd | Recombinant antibodies |
DE69233254T2 (en) * | 1991-06-14 | 2004-09-16 | Genentech, Inc., South San Francisco | Humanized Heregulin antibody |
US5582826A (en) * | 1993-04-21 | 1996-12-10 | Ajinomoto Co., Inc. | Monoclonal antibodies which bind the gamma chain of human interleukin-2 receptor |
GB9324807D0 (en) * | 1993-12-03 | 1994-01-19 | Cancer Res Campaign Tech | Tumour antibody |
US5439654A (en) | 1994-03-10 | 1995-08-08 | Steris Corporation | Cutter for opening sterilant reagent cups |
PT706799E (en) | 1994-09-16 | 2002-05-31 | Merck Patent Gmbh | IMUNOCONJUGADOS II |
AU3635695A (en) | 1994-09-19 | 1996-04-09 | Board Of Trustees Of The Leland Stanford Junior University | Methods for genetically modifying hematopoietic stem cells |
US5824762A (en) * | 1994-11-28 | 1998-10-20 | Dow Corning Toray Silicone Co., Ltd. | Organopolysiloxane and method for the preparation of the same |
AU5320296A (en) | 1995-03-24 | 1996-10-16 | Genetic Therapy, Inc. | Modified viral envelope polypeptide |
AU7435296A (en) * | 1995-10-16 | 1997-05-07 | Dana-Farber Cancer Institute | Novel expression vectors and methods of use |
AU7719596A (en) * | 1995-11-07 | 1997-05-29 | Baylor College Of Medicine | Adenovirus-mediated production of bioactive proteins by mammalian cells and animals |
JP2000500013A (en) | 1995-11-08 | 2000-01-11 | ホワイトヘッド インスティチュート フォー バイオメディカル リサーチ | Stable packaging cell line producing pseudotype retrovirus |
SE9601245D0 (en) * | 1996-03-29 | 1996-03-29 | Pharmacia Ab | Chimeric superantigens and their use |
TW517061B (en) | 1996-03-29 | 2003-01-11 | Pharmacia & Amp Upjohn Ab | Modified/chimeric superantigens and their use |
US6133027A (en) | 1996-08-07 | 2000-10-17 | City Of Hope | Inducible expression system |
US5739018A (en) | 1996-08-07 | 1998-04-14 | The Regents Of The University Of California | Packaging cell lines for pseudotyped retroviral vectors |
US6348584B1 (en) * | 1996-10-17 | 2002-02-19 | John Edward Hodgson | Fibronectin binding protein compounds |
AU747602B2 (en) * | 1997-06-04 | 2002-05-16 | Oxford Biomedica (Uk) Limited | Vector |
DE19724502C1 (en) | 1997-06-11 | 1998-10-08 | Webasto Thermosysteme Gmbh | Auxiliary heating device for motor vehicle |
WO2000009691A2 (en) * | 1998-08-10 | 2000-02-24 | Urogenesys, Inc. | Bpc-1: a secreted brain specific protein expressed and secreted by prostate and bladder cancer cells |
KR20020049054A (en) * | 1999-11-18 | 2002-06-24 | 찰스 굿맨 | Antibodies |
CN1423660A (en) | 1999-11-18 | 2003-06-11 | 牛津生物医学(英国)有限公司 | Antibodies |
-
1998
- 1998-06-04 AU AU77801/98A patent/AU747602B2/en not_active Expired
- 1998-06-04 DK DK98925827.2T patent/DK1012259T3/en active
- 1998-06-04 US US09/445,375 patent/US6852703B1/en not_active Expired - Fee Related
- 1998-06-04 WO PCT/GB1998/001627 patent/WO1998055607A2/en not_active Application Discontinuation
- 1998-06-04 ES ES98925827T patent/ES2332435T3/en not_active Expired - Lifetime
- 1998-06-04 CA CA002292760A patent/CA2292760A1/en not_active Abandoned
- 1998-06-04 AT AT98925827T patent/ATE444358T1/en active
- 1998-06-04 PT PT98925827T patent/PT1012259E/en unknown
- 1998-06-04 EP EP98925827A patent/EP1012259B1/en not_active Revoked
- 1998-06-04 JP JP50185899A patent/JP2002507117A/en active Pending
- 1998-06-04 IL IL13259698A patent/IL132596A0/en unknown
- 1998-06-04 DE DE69841204T patent/DE69841204D1/en not_active Expired - Lifetime
- 1998-06-04 NZ NZ500633A patent/NZ500633A/en not_active IP Right Cessation
- 1998-06-04 EP EP05025532A patent/EP1717248A1/en not_active Withdrawn
- 1998-06-04 CN CNB988055295A patent/CN1224712C/en not_active Expired - Lifetime
-
1999
- 1999-12-02 NO NO995901A patent/NO995901L/en not_active Application Discontinuation
-
2002
- 2002-03-22 US US10/104,522 patent/US7531648B2/en not_active Expired - Fee Related
-
2004
- 2004-02-25 US US10/787,881 patent/US20050032216A1/en not_active Abandoned
-
2006
- 2006-04-25 US US11/380,188 patent/US7718627B2/en not_active Expired - Fee Related
-
2008
- 2008-08-06 US US12/186,839 patent/US20090017532A1/en not_active Abandoned
-
2009
- 2009-04-01 JP JP2009089505A patent/JP2009153524A/en not_active Withdrawn
- 2009-11-26 CY CY20091101240T patent/CY1109686T1/en unknown
-
2010
- 2010-02-26 US US12/714,264 patent/US8084249B2/en not_active Expired - Fee Related
- 2010-08-09 JP JP2010178576A patent/JP2011000122A/en active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1989007947A1 (en) * | 1988-03-04 | 1989-09-08 | Cancer Research Campaign Technology Limited | Improvements relating to antigens |
WO1994011513A1 (en) * | 1992-11-13 | 1994-05-26 | Medical Research Council | Heat shock proteins and the treatment of tumours |
US5559099A (en) * | 1994-09-08 | 1996-09-24 | Genvec, Inc. | Penton base protein and methods of using same |
WO1996015238A1 (en) * | 1994-11-16 | 1996-05-23 | Bradley Michael John Stringer | Targeted t lymphocytes |
WO1996030512A1 (en) * | 1995-03-31 | 1996-10-03 | Rhone-Poulenc Rorer S.A. | Conditional expression system |
WO1996034969A2 (en) * | 1995-05-03 | 1996-11-07 | Canji, Inc. | Gene therapy using replication competent targeted adenoviral vectors |
Non-Patent Citations (1)
Title |
---|
CHAMBERLAIN R.S. ET AL.: "Costimulation enhances the active immunotherapy effect of recombinant anticancer vaccines", CANCER RESEARCH., vol. 56, no. 12, 15 June 1996 (1996-06-15), MD US, pages 2832 - 2836, XP002083197 * |
Also Published As
Publication number | Publication date |
---|---|
NO995901D0 (en) | 1999-12-02 |
EP1012259A2 (en) | 2000-06-28 |
CY1109686T1 (en) | 2014-08-13 |
WO1998055607A2 (en) | 1998-12-10 |
JP2002507117A (en) | 2002-03-05 |
ATE444358T1 (en) | 2009-10-15 |
US8084249B2 (en) | 2011-12-27 |
CN1224712C (en) | 2005-10-26 |
US7718627B2 (en) | 2010-05-18 |
US20030018004A1 (en) | 2003-01-23 |
PT1012259E (en) | 2009-11-06 |
US7531648B2 (en) | 2009-05-12 |
JP2011000122A (en) | 2011-01-06 |
AU7780198A (en) | 1998-12-21 |
US20090017532A1 (en) | 2009-01-15 |
DK1012259T3 (en) | 2010-01-18 |
IL132596A0 (en) | 2001-03-19 |
US6852703B1 (en) | 2005-02-08 |
CN1258319A (en) | 2000-06-28 |
US20050032216A1 (en) | 2005-02-10 |
CA2292760A1 (en) | 1998-12-10 |
EP1717248A1 (en) | 2006-11-02 |
AU747602B2 (en) | 2002-05-16 |
NZ500633A (en) | 2002-10-25 |
US20110065173A1 (en) | 2011-03-17 |
DE69841204D1 (en) | 2009-11-12 |
JP2009153524A (en) | 2009-07-16 |
US20060286634A1 (en) | 2006-12-21 |
ES2332435T3 (en) | 2010-02-04 |
NO995901L (en) | 2000-02-04 |
EP1012259B1 (en) | 2009-09-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1998055607A3 (en) | Tumor targeted vector | |
NZ335485A (en) | Isolated nucleic acid molecule encoding cancer associated antigen, the antigen itself, and uses thereof | |
EP0453560A4 (en) | Localization and characterization of the wilms's tumor gene | |
PL309403A1 (en) | Modified cutinases, dna, vector and host | |
IL109092A (en) | Tumor suppressor gene, protein expressed thereby, vectors containing said gene, and use of said vector and protein in cancer treatment | |
IL110284A0 (en) | Viral vectors and their use in gene therapy | |
WO1995013297A3 (en) | Improved immunogenic compositions against human gastrin 17 | |
AU9312198A (en) | Genes amplified in tumours, antibodies against the proteins encoded thereby, andtheir use in diagnosis and treatment of cancer | |
NZ237198A (en) | Zymogen form of protein c, dna, vector and use as a pharmaceutical | |
GR3036979T3 (en) | Coupling product obtained from hystamine and an amino acid. | |
GB9323429D0 (en) | Therapy | |
PL309388A1 (en) | Modified cutinases, dna, vector and host | |
AU1384995A (en) | Human circulating cytokine cc-1 | |
AU5847194A (en) | Novel entomopoxvirus genes, proteins and methods of use thereof | |
AU3574900A (en) | Human cervical cancer 1 protooncogene and protein encoded therein | |
CA2117795A1 (en) | Gustducin Materials and Methods | |
WO1999033989A3 (en) | Rantes mutants and therapeutic applications thereof | |
AU1099697A (en) | Novel xylanases, genes encoding them, and uses thereof | |
WO2001014415A3 (en) | Egfh2 genes and gene products | |
ZA9610510B (en) | Novel peptides, the preparation and use thereof. | |
AU4860299A (en) | (zap-3) tumor associated genes and their uses | |
CA2332321A1 (en) | An incapacitant comprising pava | |
WO1998050397A3 (en) | Chimeric oligonucleotides and the use thereof | |
AU3928193A (en) | Plasmilar gene, peptide and methods of use | |
AU1209797A (en) | Novel antigenic proteins of mycoplasmata, genes thereof, and recombinant vector and use of the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 132596 Country of ref document: IL Ref document number: 98805529.5 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 500633 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 77801/98 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2292760 Country of ref document: CA Ref document number: 2292760 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1019997011207 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1998925827 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09445375 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1998925827 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1019997011207 Country of ref document: KR |
|
WWG | Wipo information: grant in national office |
Ref document number: 77801/98 Country of ref document: AU |
|
WWR | Wipo information: refused in national office |
Ref document number: 1019997011207 Country of ref document: KR |